EntryPoint Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
Other funds holding RARE
RI
FCM
EntryPoint Capital's RARE Position: Q2 2026 in Review
EntryPoint Capital reduced its Ultragenyx Pharmaceutical (RARE) stake by 1.4% in Q2 2026, selling an estimated $8.77K and leaving 25,766 shares worth $860K. The position accounts for 0.21% of the portfolio, ranked #119.
EntryPoint Capital first reported a position in RARE in Q1 2024 and has held it in 8 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- EntryPoint Capital held 25,766 shares of Ultragenyx Pharmaceutical worth $860K as of Q2 2026.
- EntryPoint Capital sold 353 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $8.77K.
- Ultragenyx Pharmaceutical made up 0.21% of EntryPoint Capital's portfolio in Q2 2026, its #119 holding.
- EntryPoint Capital first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and has held it in 8 quarters since.
- 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.